It's a deadly cancer with a complicated name and for too long there've been limited treatment options for sufferers, until ...

肝内胆管癌 (intrahepatic cholangiocarcinoma, iCCA)的预后不佳，很大原因是由于诊断不够及时造成的，因此iCCA的早期诊断和及早治疗是提高疾病治愈效果的 ...

Cholangiocarcinoma, also known as bile duct cancer, is a rare disease. It's a devasting condition incurable at the point ...

Tinengotinib in patients with advanced, metastatic cholangiocarcinoma: Overall survival results and biomarker correlative analysis from a phase 2 clinical trial.

The magnetic resonance (MR) imaging appearance of cholangiocarcinoma depends on the amount of fibrosis, necrosis, and mucinous material within the tumor. Most frequently it appears as a ...

Adjuvant chemoradiation combined with camrelizumab was well tolerated and yielded significantly improved long-term survival,” the researchers wrote.

SAN DIEGO — A one-unit increase in cholangioscopy procedures was linked to a 24% increase in subsequent cholangiocarcinoma diagnoses the following year, according to research presented at ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

Cholangiocarcinoma, known more commonly as bile duct (or biliary) cancer, has several features that historically have made it difficult to treat. First, it is a rare cancer, so advances in treatment ...

Futibatinib, an inhibitor of fibroblast growth factor receptors 1–4, has shown promising antitumor activity in patients with intrahepatic cholangiocarcinoma with FGFR2 fusions or rearrangements ...

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has ...

Cholangiocarcinoma is a rare cancer that develops from the bile ducts, which are slender tubes that carry the digestive fluid bile and connect the liver to the gallbladder and small intestine.